Acquisition Opportunity Nexcelom was acquired by PerkinElmer in 2021 for 260 million, indicating a large corporate distribution and potential cross-sell channels for Revvity portfolio products in life science imaging and cell analysis.

High Throughput Demand Celigo high throughput image cytometry systems target adherent and suspension cells in microwell plates, suggesting strong upsell potential to labs expanding screening, HTS assays, and translational research pipelines.

Imaging & Viability Product lines include Cellometer cell viability counters and fluorescence imaging, offering cross-sell opportunities with reagents, consumables, and advanced imaging workflows for cancer, stem cell, immunology, and neuroscience research.

Global Expansion With headquarters in Boston and over 80 global employees, Nexcelom has established manufacturing and customer-facing capabilities that can support regional expansions, channel partnerships, and OEM opportunities within Revvity’s life sciences ecosystem.

Strategic Partnerships Past investments and deals (Ampersand Capital, PerkinElmer) indicate readiness for strategic partnerships and co-development of new imaging cytometry platforms, consumables, and data software within a broader Revvity portfolio.